{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:21:22Z","timestamp":1774956082583,"version":"3.50.1"},"reference-count":40,"publisher":"Bentham Science Publishers Ltd.","issue":"9","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703512"],"award-info":[{"award-number":["81703512"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>This study aimed to prepare combretastatin A4 (CA4)-loaded nanoparticles (CA4\nNPs) using poly(lactic-co-glycolic acid) (PLGA) and soybean lecithin (Lipoid S100) as carriers, and\nfurther evaluate the physicochemical properties and cytotoxicities of CA4 NPs against cancer cells.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>CA4 NPs were prepared using a solvent evaporation technique. The effects of formulations\non CA4 NPs were investigated in terms of particle size, zeta potential, encapsulation efficacy, and drug\nloading. The physicochemical properties of CA4 NPs were characterized using transmission electron\nmicroscopy, X-ray powder diffraction, differential scanning calorimetry, and Fourier transform infrared\nspectra. The drug release from CA4NPs was performed using a dialysis method. In addition, the cytotoxicity\nof CA4NPs against human alveolar basal epithelial (A549) cells was also evaluated.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>CA4 NPs prepared with a low organic\/water phase ratio (1:20) and high drug\/PLGA mass ratio\n(1:2.5) exhibited a uniform hydrodynamic particle size of 142 nm, the zeta potential of -1.66 mV, and\nencapsulation efficacy and drug loading of 92.1% and 28.3%, respectively. CA4 NPs showed a significantly\nhigher release rate than pure CA4 in pH 7.4 phosphate-buffered solution with 0.5% Tween 80. It\nwas found that the drug molecules could change from the crystal state to an amorphous form when\nloaded into the PLGA\/Lipoid S100 matrix, and some molecular interactions could also occur between\nthe drug and PLGA. Importantly, CA4 NPs showed a remarkably higher antiproliferation activity\nagainst A549 cancer cells compared to pure CA4.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>These results suggested the promising potential of PLGA\/Lipoid S100 nanoparticles as the\ndrug delivery system of CA4 for effective cancer therapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1567201819666220209093443","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T04:59:33Z","timestamp":1644469173000},"page":"918-927","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Combretastatin A4-loaded Poly (Lactic-co-glycolic Acid)\/Soybean Lecithin Nanoparticles with Enhanced Drug Dissolution Rate and Antiproliferation Activity"],"prefix":"10.2174","volume":"19","author":[{"given":"Jing","family":"Tao","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou 215006, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-Ri","family":"Cao","sequence":"first","affiliation":[{"name":"College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Health Vocational College, Beijing 100053, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atef Mohammed Qasem","family":"Ahmed","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan-Huan","family":"Du","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojuan","family":"Lu","sequence":"additional","affiliation":[{"name":"PharmaMax Pharmaceuticals, Ltd., China Medical City, Taizhou 225300, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao","family":"Xu","sequence":"additional","affiliation":[{"name":"PharmaMax Pharmaceuticals, Ltd., China Medical City, Taizhou 225300, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"Hanahan D.","year":"2011","unstructured":"Hanahan D.; Weinberg R.A.; Hallmarks of cancer: The next generation. Cell 2011,144(5),646-674","journal-title":"Cell"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/35025220","volume":"407","author":"Carmeliet P.","year":"2000","unstructured":"Carmeliet P.; Jain R.K.; Angiogenesis in cancer and other diseases. Nature 2000,407(6801),249-257","journal-title":"Nature"},{"key":"ref=3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081172","volume":"11","author":"Pedrosa L.","year":"2019","unstructured":"Pedrosa L.; Esposito F.; Thomson T.M.; Maurel J.; The tumor microenvironment in colorectal cancer therapy. Cancers (Basel) 2019,11(8)","journal-title":"Cancers (Basel)"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/labinvest.3700526","volume":"87","author":"Shojaei F.","year":"2007","unstructured":"Shojaei F.; Ferrara N.; Antiangiogenesis to treat cancer and intraocular neovascular disorders. Lab Invest 2007,87(3),227-230","journal-title":"Lab Invest"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41571-019-0181-9","volume":"16","author":"Kuczynski E.A.","year":"2019","unstructured":"Kuczynski E.A.; Vermeulen P.B.; Pezzella F.; Kerbel R.S.; Reynolds A.R.; Vessel co-option in cancer. Nat Rev Clin Oncol 2019,16(8),469-493","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"15885","DOI":"10.3390\/ijms140815885","volume":"14","author":"Gavalas N.G.","year":"2013","unstructured":"Gavalas N.G.; Liontos M.; Trachana S.P.; Bagratuni T.; Arapinis C.; Liacos C.; Dimopoulos M.A.; Bamias A.; Angiogenesis-related pathways in the pathogenesis of ovarian cancer. Int J Mol Sci 2013,14(8),15885-15909","journal-title":"Int J Mol Sci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","volume":"285","author":"Folkman J.","year":"1971","unstructured":"Folkman J.; Tumor angiogenesis: therapeutic implications. N Engl J Med 1971,285(21),1182-1186","journal-title":"N Engl J Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00262-019-02317-9","volume":"68","author":"Quillien V.","year":"2019","unstructured":"Quillien V.; Carpentier A.F.; Gey A.; Avril T.; Tartour E.; Sejalon F.; Campillo-Gimenez B.; Vauleon E.; Absolute numbers of regulatory T cells and neutrophils in corticosteroid-free patients are predictive for response to bevacizumab in recurrent glioblastoma patients. Cancer Immunol Immunother 2019,68(6),871-882","journal-title":"Cancer Immunol Immunother"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","volume":"393","author":"Rini B.I.","year":"2019","unstructured":"Rini B.I.; Powles T.; Atkins M.B.; Escudier B.; McDermott D.F.; Suarez C.; Bracarda S.; Stadler W.M.; Donskov F.; Lee J.L.; Hawkins R.; Ravaud A.; Alekseev B.; Staehler M.; Uemura M.; De Giorgi U.; Mellado B.; Porta C.; Melichar B.; Gurney H.; Bedke J.; Choueiri T.K.; Parnis F.; Khaznadar T.; Thobhani A.; Li S.; Piault-Louis E.; Frantz G.; Huseni M.; Schiff C.; Green M.C.; Motzer R.J.; Group I.M.S.; Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019,393(10189),2404-2415","journal-title":"Lancet"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ejphar.2012.08.023","volume":"695","author":"Su J.","year":"2012","unstructured":"Su J.; Laursen B.E.; Eskildsen-Helmond Y.; Horsman M.R.; Simonsen U.; The vascular-disrupting agent, combretastatin-A4-phosphate, enhances neurogenic vasoconstriction in rat small arteries. Eur J Pharmacol 2012,695(1-3),104-111","journal-title":"Eur J Pharmacol"},{"key":"ref=11","doi-asserted-by":"publisher","DOI":"10.3390\/molecules21111468","volume":"21","author":"Banerjee S.","year":"2016","unstructured":"Banerjee S.; Hwang D.J.; Li W.; Miller D.D.; Current advances of tubulin inhibitors in nanoparticle drug delivery and vascular disrup-tion\/angiogenesis. Molecules 2016,21(11)","journal-title":"Molecules"},{"key":"ref=12","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28230","author":"Nik M.E.","year":"2019","unstructured":"Nik M.E.; Momtazi-Borojeni A.A.; Zamani P.; Navashenaq J.G.; Iranshahi M.; Jaafari M.R.; Malaekeh-Nikouei B.; Targeted-nanoliposomal combretastatin A-4 (CA-4) as an efficient antivascular candidate in the metastatic cancer treatment. J Cell Physiol 2019","journal-title":"J Cell Physiol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/00001813-200403000-00001","volume":"15","author":"West C.M.","year":"2004","unstructured":"West C.M.; Price P.; Combretastatin A4 phosphate. Anticancer Drugs 2004,15(3),179-187","journal-title":"Anticancer Drugs"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrc1628","volume":"5","author":"Tozer G.M.","year":"2005","unstructured":"Tozer G.M.; Kanthou C.; Baguley B.C.; Disrupting tumour blood vessels. Nat Rev Cancer 2005,5(6),423-435","journal-title":"Nat Rev Cancer"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2050-6511-14-7","volume":"14","author":"Ibrahim M.A.","year":"2013","unstructured":"Ibrahim M.A.; Do D.V.; Sepah Y.J.; Shah S.M.; Van Anden E.; Hafiz G.; Donahue J.K.; Rivers R.; Balkissoon J.; Handa J.T.; Campochiaro P.A.; Nguyen Q.D.; Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate. BMC Pharmacol Toxicol 2013,14,7","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/annonc\/mdr332","volume":"23","author":"Ng Q.S.","year":"2012","unstructured":"Ng Q.S.; Mandeville H.; Goh V.; Alonzi R.; Milner J.; Carnell D.; Meer K.; Padhani A.R.; Saunders M.I.; Hoskin P.J.; Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Ann Oncol 2012,23(1),231-237","journal-title":"Ann Oncol"},{"key":"ref=17","first-page":"3408","volume":"62","author":"Dowlati A.","year":"2002","unstructured":"Dowlati A.; Robertson K.; Cooney M.; Petros W.P.; Stratford M.; Jesberger J.; Rafie N.; Overmoyer B.; Makkar V.; Stambler B.; Taylor A.; Waas J.; Lewin J.S.; McCrae K.R.; Remick S.C.; A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002,62(12),3408-3416","journal-title":"Cancer Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.2003.05.185","volume":"21","author":"Rustin G.J.","year":"2003","unstructured":"Rustin G.J.; Galbraith S.M.; Anderson H.; Stratford M.; Folkes L.K.; Sena L.; Gumbrell L.; Price P.M.; Phase I clinical trial of weekly combretastatin A-4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003,21(15),2815-2822","journal-title":"J Clin Oncol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1517\/13543784.13.9.1171","volume":"13","author":"Young S.L.","year":"2004","unstructured":"Young S.L.; Chaplin D.J.; Combretastatin A4 phosphate: background and current clinical status. Expert Opin Investig Drugs 2004,13(9),1171-1182","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1158\/1078-0432.CCR-0364-3","volume":"10","author":"Cooney M.M.","year":"2004","unstructured":"Cooney M.M.; Radivoyevitch T.; Dowlati A.; Overmoyer B.; Levitan N.; Robertson K.; Levine S.L.; DeCaro K.; Buchter C.; Taylor A.; Stambler B.S.; Remick S.C.; Cardiovascular safety profile of combretastatin A-4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 2004,10(1 Pt 1),96-100","journal-title":"Clin Cancer Res"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/j.1365-2125.2011.03928.x","volume":"71","author":"He X.","year":"2011","unstructured":"He X.; Li S.; Huang H.; Li Z.; Chen L.; Ye S.; Huang J.; Zhan J.; Lin T.; A pharmacokinetic and safety study of single dose intravenous combretastatin A-4 phosphate in Chinese patients with refractory solid tumours. Br J Clin Pharmacol 2011,71(6),860-870","journal-title":"Br J Clin Pharmacol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/sj.bjc.6692174","volume":"81","author":"Grosios K.","year":"1999","unstructured":"Grosios K.; Holwell S.E.; McGown A.T.; Pettit G.R.; Bibby M.C.; In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 1999,81(8),1318-1327","journal-title":"Br J Cancer"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/j.bioactmat.2020.12.010","volume":"6","author":"Yang M.","year":"2020","unstructured":"Yang M.; Li J.; Gu P.; Fan X.; The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment. Bioact Mater 2020,6(7),1973-1987","journal-title":"Bioact Mater"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.4172\/2157-7439.1000519","volume":"9","author":"Zhao N.","year":"2018","unstructured":"Zhao N.; Woodle M.C.; Mixson A.J.; Advances in delivery systems for doxorubicin. J Nanomed Nanotechnol 2018,9(5),519","journal-title":"J Nanomed Nanotechnol"},{"key":"ref=25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051960","volume":"7","author":"Golla K.","year":"2012","unstructured":"Golla K.; Cherukuvada B.; Ahmed F.; Kondapi A.K.; Efficacy, safety and anticancer activity of protein nanoparticle-based delivery of dox-orubicin through intravenous administration in rats. PLoS One 2012,7(12)","journal-title":"PLoS One"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1007\/s11095-013-1262-6","volume":"31","author":"Qi F.","year":"2014","unstructured":"Qi F.; Wu J.; Hao D.; Yang T.; Ren Y.; Ma G.; Su Z.; Comparative studies on the influences of primary emulsion preparation on proper-ties of uniform-sized exenatide-loaded PLGA microspheres. Pharm Res 2014,31(6),1566-1574","journal-title":"Pharm Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.msec.2017.12.036","volume":"92","author":"Ding D.","year":"2018","unstructured":"Ding D.; Zhu Q.; Recent advances of PLGA micro\/nanoparticles for the delivery of biomacromolecular therapeutics. Mater Sci Eng C 2018,92,1041-1060","journal-title":"Mater Sci Eng C"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1080\/21645515.2015.1117714","volume":"12","author":"Silva A.L.","year":"2016","unstructured":"Silva A.L.; Soema P.C.; Sl\u00fctter B.; Ossendorp F.; Jiskoot W.; PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity. Hum Vaccin Immunother 2016,12(4),1056-1069","journal-title":"Hum Vaccin Immunother"},{"key":"ref=29","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/415289","volume":"2015","author":"Ortega-Oller I.","year":"2015","unstructured":"Ortega-Oller I.; Padial-Molina M.; Galindo-Moreno P.; O\u2019Valle F.; J\u00f3dar-Reyes A.B.; Peula-Garc\u00eda J.M.; Bone regeneration from PLGA micro-nanoparticles. BioMed Res Int 2015,2015","journal-title":"BioMed Res Int"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"7181","DOI":"10.1016\/j.biomaterials.2013.05.081","volume":"34","author":"Wang Y.","year":"2013","unstructured":"Wang Y.; Chen H.; Liu Y.; Wu J.; Zhou P.; Wang Y.; Li R.; Yang X.; Zhang N.; pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma. Biomaterials 2013,34(29),7181-7190","journal-title":"Biomaterials"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijpharm.2011.05.036","volume":"427","author":"Xu J.","year":"2012","unstructured":"Xu J.; Ganesh S.; Amiji M.; Non-condensing polymeric nanoparticles for targeted gene and siRNA delivery. Int J Pharm 2012,427(1),21-34","journal-title":"Int J Pharm"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0378-5173(02)00315-0","volume":"244","author":"Prabha S.","year":"2002","unstructured":"Prabha S.; Zhou W.Z.; Panyam J.; Labhasetwar V.; Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. Int J Pharm 2002,244(1-2),105-115","journal-title":"Int J Pharm"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1208\/s12249-009-9199-0","volume":"10","author":"Bhalekar M.R.","year":"2009","unstructured":"Bhalekar M.R.; Pokharkar V.; Madgulkar A.; Patil N.; Patil N.; Preparation and evaluation of miconazole nitrate-loaded solid lipid nanopar-ticles for topical delivery. AAPS PharmSciTech 2009,10(1),289-296","journal-title":"AAPS PharmSciTech"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3109\/10717544.2014.903012","volume":"23","author":"Xu W.J.","year":"2016","unstructured":"Xu W.J.; Xie H.J.; Cao Q.R.; Shi L.L.; Cao Y.; Zhu X.Y.; Cui J.H.; Enhanced dissolution and oral bioavailability of valsartan solid disper-sions prepared by a freeze-drying technique using hydrophilic polymers. Drug Deliv 2016,23(1),41-48","journal-title":"Drug Deliv"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ijpharm.2012.05.076","volume":"434","author":"Cao Q.R.","year":"2012","unstructured":"Cao Q.R.; Liu Y.; Xu W.J.; Lee B.J.; Yang M.; Cui J.H.; Enhanced oral bioavailability of novel mucoadhesive pellets containing valsartan prepared by a dry powder-coating technique. Int J Pharm 2012,434(1-2),325-333","journal-title":"Int J Pharm"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1038\/s41467-018-05061-3","volume":"9","author":"Yu M.","year":"2018","unstructured":"Yu M.; Xu L.; Tian F.; Su Q.; Zheng N.; Yang Y.; Wang J.; Wang A.; Zhu C.; Guo S.; Zhang X.; Gan Y.; Shi X.; Gao H.; Rapid transport of deformation-tuned nanoparticles across biological hydrogels and cellular barriers. Nat Commun 2018,9(1),2607","journal-title":"Nat Commun"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"9763","DOI":"10.1021\/acsami.8b20810","volume":"11","author":"Cao Y.","year":"2019","unstructured":"Cao Y.; Huang H.Y.; Chen L.Q.; Du H.H.; Cui J.H.; Zhang L.W.; Lee B.J.; Cao Q.R.; Enhanced lysosomal escape of pH-responsive poly-ethylenimine-betaine functionalized carbon nanotube for the codelivery of survivin small interfering RNA and doxorubicin. ACS Appl Mater Interfaces 2019,11(10),9763-9776","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijpharm.2018.03.017","volume":"543","author":"Li B.","year":"2018","unstructured":"Li B.; Zhang X.X.; Huang H.Y.; Chen L.Q.; Cui J.H.; Liu Y.; Jin H.; Lee B.J.; Cao Q.R.; Effective deactivation of A549 tumor cells in vitro and in vivo by RGD-decorated chitosan-functionalized single-walled carbon nanotube loading docetaxel. Int J Pharm 2018,543(1-2),8-20","journal-title":"Int J Pharm"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1021\/acs.molpharmaceut.6b00226","volume":"13","author":"Shi L.L.","year":"2016","unstructured":"Shi L.L.; Xie H.; Lu J.; Cao Y.; Liu J.Y.; Zhang X.X.; Zhang H.; Cui J.H.; Cao Q.R.; Positively charged surface-modified solid lipid na-noparticles promote the intestinal transport of docetaxel through multifunctional mechanisms in rats. Mol Pharm 2016,13(8),2667-2676","journal-title":"Mol Pharm"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ijpharm.2014.11.017","volume":"478","author":"Shi L.L.","year":"2015","unstructured":"Shi L.L.; Cao Y.; Zhu X.Y.; Cui J.H.; Cao Q.R.; Optimization of process variables of zanamivir-loaded solid lipid nanoparticles and the prediction of their cellular transport in Caco-2 cell model. Int J Pharm 2015,478(1),60-69","journal-title":"Int J Pharm"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567201819666220209093443","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/200944\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567201819666220209093443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T16:28:18Z","timestamp":1662049698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/200944\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567201819666220209093443","relation":{},"ISSN":["1567-2018"],"issn-type":[{"value":"1567-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-06-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}